Microbiological efficacy of intravenous immunoglobulins in the complex treatment of tracheobronchitis in premature infants

Material and methods: We investigated the microbiological efficacy of intravenous immunoglobulins (IVIG) in 34 premature newborns (birth weight was from 960 to 2750 g) with respiratory distress syndrome, those who were on hardware artificial ventilation of the lungs. The infectious complications did not develop in 20 infants (group I), and tracheobronchitis developed in 14 infants (group II). The infants in group II, along with basic therapy, received IVIG from the second day of life for three consecutive days. Results: The use of IVIG showed a high microbiological efficiency, which was in 86% of patients within a day from the start of treatment. The greatest inhibition of growth is observed in relation to bacterial microflora and intracellular microorganisms. The lowest effect was shown in relation to Candida albicans. A stable effect of IVIG was observed in all newborns within three days after the course of immunotherapy.